New Challenges in the Management of Pulmonary Toxicities
Pulmonary function is important to maintaining homeostasis and dysfunction can result in life-threatening complications. There is a need to discuss the incidence, prevention, and management of pulmonary toxicities given that numerous cancer treatments have the potential to cause pulmonary dysfunction. Clinician education on this topic can help them provide optimal care for patients experiencing pulmonary toxicity.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • 0.75 ANCC contact hours
  • 0.75 Participation
Management of Acute Hyperglycemia
Hyperglycemia is a common complication of cancer and its treatments. Appropriate monitoring and management of hyperglycemia is critical to prevent glycemic emergencies and optimize response to chemotherapy.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • 0.75 ANCC contact hours
  • 0.75 Participation
Updates in Biomarker Testing in Non-Small Cell Lung Cancer
Biomarker testing is becoming more important due to the shift in cancer care to targeted therapies. Especially in NSCLC, there are many new updates in which biomarkers should be tested, when testing is required or recommended, and what the barriers are to implementing testing for all patients.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 ANCC contact hours
  • 0.75 Participation
Harm Reduction Strategies for Substance Use in Patients with Cancer
Patients with cancer are at risk of substance use disorder (SUD), which is commonly misunderstood and inappropriately managed. Understanding the basis of addiction and applying harm reduction principles to patients living with SUD presents an opportunity to enhance patient care.
Category
  • Supportive Care Topics
Format
  • Recorded Webcast
Credits
  • 0.75 ANCC contact hours
  • 0.75 Participation
How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies
Educating clinicians about the various strategies that can be employed to improve the effective delivery of anticancer therapy will enable the incorporation of these strategies into routine clinical practice. 
Category
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey
Clinicians need to be educated on the vast and varied impact cancer can have on individuals, the barriers to receipt of high-quality care, and the various professionals who can be part of their team to provide comprehensive care and improve patient outcomes. Information on approaches to build, maintain, and support such teams is also needed so that patients can benefit.
Category
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Management of Central Nervous System Metastases
As a result of advances in diagnosis and treatment, many patients improve with proper management and do not die of progression of these metastatic lesions. As CNS-active systemic agents are changing paradigms for the management of brain metastases, it is important to acknowledge that there is a paucity of prospective data to characterize optimal strategies regarding radiation and systemic therapy combinations or sequencing.
Category
  • Central Nervous System Cancers
  • Central Nervous System Cancers
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Team-Based Management of Immunotherapy-Related Toxicities
Education on this topic will enable clinicians to more rapidly identify when they may need to seek the expertise of disease specialists, and which specialists may be most relevant to their patients’ needs.
Category
  • Management of Immunotherapy-Related Toxicities
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Archived Monthly Oncology Tumor Boards: Neoadjuvant and Adjuvant Therapy for Patients with Resectable Early-Stage and Locally Advanced Non-Small Cell Lung Cancer
Clinicians need to know the nuances of using neoadjuvant and adjuvant targeted therapy and immunotherapy to improve outcomes for their patients with resected early-stage and locally advanced NSCLC.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Changing Treatment Paradigms in Chronic Lymphocytic Leukemia
Since not all patients have access to a CLL specialist, the oncology pharmacist assumes an important role in understanding the best available clinical research, pairing that with the individual patient, and evaluating the outcomes to optimize patient care.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Pages